Mohit Bansal
Stock Analyst at Wells Fargo
(4.14)
# 435
Out of 4,840 analysts
164
Total ratings
58.33%
Success rate
10.25%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $50 → $47 | $29.75 | +57.98% | 2 | May 13, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $60 → $65 | $54.54 | +19.18% | 7 | May 7, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $750 → $700 | $588.34 | +18.98% | 17 | Apr 30, 2025 | |
| IRWD Ironwood Pharmaceuticals | Downgrades: Equal-Weight | $7 → $1 | $0.57 | +76.58% | 4 | Apr 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $970 → $1,100 | $713.71 | +54.12% | 17 | Mar 5, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $140 | $107.37 | +30.39% | 11 | Mar 5, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $240 | $183.26 | +30.96% | 8 | Mar 5, 2025 | |
| BIIB Biogen | Maintains: Equal-Weight | $165 → $140 | $125.81 | +11.28% | 13 | Feb 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Upgrades: Overweight | $130 → $170 | $108.07 | +57.31% | 2 | Feb 13, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $60 → $62 | $46.85 | +32.34% | 8 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $460 | $436.00 | +5.50% | 10 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $335 → $280 | $271.66 | +3.07% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $25.85 | +16.05% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $170 | $98.68 | +72.27% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $19.64 | +256.42% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $125 → $110 | $77.58 | +41.79% | 10 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $27 | $15.84 | +70.45% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $90 | $57.55 | +56.39% | 5 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $23.32 | +28.64% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $120.18 | +41.45% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $15.96 | +69.17% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $8.49 | +21,984.81% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $30 | $29.61 | +1.33% | 4 | Jan 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $1.08 | +3,233.33% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $12.69 | +49.72% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $5 | $0.28 | +1,685.08% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.54 | +3,796.10% | 4 | Dec 3, 2019 |
Xenon Pharmaceuticals
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $29.75
Upside: +57.98%
Halozyme Therapeutics
May 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $65
Current: $54.54
Upside: +19.18%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Overweight
Price Target: $750 → $700
Current: $588.34
Upside: +18.98%
Ironwood Pharmaceuticals
Apr 15, 2025
Downgrades: Equal-Weight
Price Target: $7 → $1
Current: $0.57
Upside: +76.58%
Eli Lilly and Company
Mar 5, 2025
Maintains: Overweight
Price Target: $970 → $1,100
Current: $713.71
Upside: +54.12%
Gilead Sciences
Mar 5, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $107.37
Upside: +30.39%
AbbVie
Mar 5, 2025
Maintains: Overweight
Price Target: $210 → $240
Current: $183.26
Upside: +30.96%
Biogen
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $165 → $140
Current: $125.81
Upside: +11.28%
Jazz Pharmaceuticals
Feb 13, 2025
Upgrades: Overweight
Price Target: $130 → $170
Current: $108.07
Upside: +57.31%
Bristol-Myers Squibb Company
Feb 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $62
Current: $46.85
Upside: +32.34%
Jan 30, 2025
Downgrades: Equal-Weight
Price Target: $460
Current: $436.00
Upside: +5.50%
Jan 10, 2025
Maintains: Equal-Weight
Price Target: $335 → $280
Current: $271.66
Upside: +3.07%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $25.85
Upside: +16.05%
Dec 11, 2024
Initiates: Overweight
Price Target: $170
Current: $98.68
Upside: +72.27%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $19.64
Upside: +256.42%
Nov 1, 2024
Maintains: Equal-Weight
Price Target: $125 → $110
Current: $77.58
Upside: +41.79%
Oct 21, 2024
Upgrades: Overweight
Price Target: $9 → $27
Current: $15.84
Upside: +70.45%
Sep 17, 2024
Maintains: Overweight
Price Target: $115 → $90
Current: $57.55
Upside: +56.39%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $23.32
Upside: +28.64%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $120.18
Upside: +41.45%
Mar 7, 2023
Initiates: Overweight
Price Target: $27
Current: $15.96
Upside: +69.17%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $8.49
Upside: +21,984.81%
Jan 7, 2021
Maintains: Buy
Price Target: $25 → $30
Current: $29.61
Upside: +1.33%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $1.08
Upside: +3,233.33%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $12.69
Upside: +49.72%
Apr 27, 2020
Maintains: Buy
Price Target: $8 → $5
Current: $0.28
Upside: +1,685.08%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.54
Upside: +3,796.10%